Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2016 01:39 ET | Source: MorphoSys AG

MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL

MARTINSRIED / MUNICH, Germany, Sept. 6, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient has been dosed in the safety...
August 29, 2016 09:09 ET | Source: MorphoSys AG

MorphoSys to Present at Upcoming Investor Conferences

MARTINSRIED / MUNICH, Germany, Aug. 29, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: Commerzbank Sector...
August 03, 2016 01:32 ET | Source: MorphoSys AG

MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients with DLBCL

MARTINSRIED / MUNICH, Germany, Aug. 3, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has successfully completed the safety run-in...
August 01, 2016 01:06 ET | Source: MorphoSys AG

MorphoSys AG Reports Results for the First Six Months of 2016

Financial Guidance for 2016 Confirmed Conference call and webcast (in English) today at 2:00pm CEST (1:00pm BST/8:00am EDT) MARTINSRIED / MUNICH, Germany, Aug. 1, 2016 (GLOBE NEWSWIRE)...
July 25, 2016 08:07 ET | Source: MorphoSys AG

MorphoSys to Host Q2 2016 Conference Call on August 1, 2016

MARTINSRIED and MUNICH, Germany, July 25, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2016 results on August 1, 2016 at 7:00 am...
July 04, 2016 01:32 ET | Source: MorphoSys AG

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody

MARTINSRIED / MUNICH, Germany, July 4, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has received a milestone payment from...
June 17, 2016 02:16 ET | Source: MorphoSys AG

MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of Currently 26 Months under MOR208 Treatment

MARTINSRIED / MUNICH, Germany, June 17, 2016 (GLOBE NEWSWIRE) -- Case study from clinical phase 2a trial with MOR208 in relapsed/refractory NHL published in the Journal of Medical Case...
June 06, 2016 09:46 ET | Source: MorphoSys AG

MorphoSys Presents Updated Clinical Data for MOR202 in Multiple Myeloma and for MOR208 in Non-Hodgkin's Lymphoma at ASCO 2016

MARTINSRIED and MUNICH, Germany, June 6, 2016 (GLOBE NEWSWIRE) -- MOR202 Combination Therapy with Complete Remissions in Multiple Myeloma MOR202 (8 mg/kg) plus Pom/Dex in relapsed/refractory multiple...
June 02, 2016 09:26 ET | Source: MorphoSys AG

MorphoSys AG Reports Outcome of Annual General Meeting 2016

MARTINSRIED and MUNICH, Germany, June 2, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) reported the outcome of the Company's Annual General Meeting, which took place...
June 01, 2016 08:06 ET | Source: MorphoSys AG

MorphoSys to Present at Six Upcoming Conferences

MARTINSRIED and MUNICH, Germany, June 1, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: MorphoSys Investor...